TAILIEUCHUNG - Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: A retrospective study

Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors can guide the selection of eribulin or capecitabine in this setting, and prognostic factors are needed to guide appropriate treatment selection. | Takamizawa et al. BMC Cancer 2022 22 64 https s12885-021-09112-9 RESEARCH Open Access Neutrophil to lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine a retrospective study Shigemasa Takamizawa Tatsunori Shimoi Natsuko Satomi Tsushita Shu Yazaki Toshihiro Okuya Yuki Kojima Hitomi Sumiyoshi Okuma Tadaaki Nishikawa Maki Tanioka Kazuki Sudo Emi Noguchi and Kan Yonemori Abstract Background Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However it is unclear what factors can guide the selection of eribulin or capecitabine in this setting and prognostic factors are needed to guide appropriate treatment selection. The neutrophil-to-lymphocyte ratio NLR is a prognostic factor for eribulin- treated patients although it is unclear whether it is a prognostic factor for capecitabine-treated patients. Therefore we analysed the ability of the NLR to predict oncological outcomes among patients who received capecitabine after previous anthracycline or taxane treatment for breast cancer. Methods We retrospectively reviewed the medical records of patients with metastatic or recurrent breast cancer who had previously received anthracycline or taxane treatment at the National Cancer Center Hospital between 2007 and 2015. Patients were included if they received eribulin or capecitabine monotherapy as first-line second-line or third-line chemotherapy. Analyses of overall survival OS and progression-free survival PFS were performed accord ing to various factors. Results Between 2007 and 2015 we identified 125 eligible patients including 46 patients who received only eribu lin 34 patients who received only capecitabine and 45 patients who received eribulin and capecitabine. The median follow-up period was months. Among eribulin-treated patients an NLR

• Y khoa - Dược
• BMC Cancer
• Breast cancer
• Neutrophil to lymphocyte ratio
• Prognostic factor
• Capecitabine monotherapy
• Cytotoxic chemotherapy
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study